Phase 5 · Virtual Verification & Clinical Translation
Virtual Prototyping, Validation & Clinical IRB Protocols
Assembling the complete digital twin simulation pipeline, statistical power modeling for clinical validation, ethical human subjects protections (IRB), and pitch symposium readiness.
Course: IDNE 701 (Fall 2026)
Date: Nov 20, 2026 (Week 13)
Duration: 80 Minutes
Instructor: Mark Bolding, PhD
01. The End-to-End Virtual Prototype Pipeline
Prior to physical fabricating costly medical hardware, neuroengineers build an integrated computational digital twin encompassing four coupled simulation stages:
1. Biological Substrate Model
High-resolution 3D anatomical mesh (voxelized or boundary element) assigned with tissue physical tensors: electrical conductivity $\sigma(\vec{r})$, optical absorption/scattering $\mu_a, \mu_s'$, and acoustic impedance $Z(\vec{r})$.
2. Forward Field Physics
Numerical solution of Maxwell, Diffusion, or Wave equations producing synthetic noise-free sensor signals $\mathbf{y}_0 = \mathbf{A}(\mathbf{x})$.
3. Front-End Noise & Movement
Injection of thermal Johnson noise, preamplifier noise figure, motion displacement vectors ($\mathbf{R}, \vec{T}$), and physiological baseline drift.
4. Inversion & Diagnostic Metric
Execution of the reconstruction and ML biomarker pipeline to output clinical classifications with quantified ROC-AUC and RMSE error.
02. Clinical Study Design & IRB Submission
Translating an engineering prototype into clinical utility requires an Institutional Review Board (IRB) approved protocol following 45 CFR 46 (The Common Rule):
🎯 Primary & Secondary Endpoints
Clearly defined, measurable clinical hypotheses (e.g., sensitivity of optical FTOE in detecting HIE autoregulation failure compared to MRI diffusion restricted lesions at day 4).
📊 Statistical Sample Size Power Analysis
Computing minimum subject cohort size $N$ based on type I error $\alpha = 0.05$ and statistical power $1 - \beta = 0.80$:
$$N = \frac{2 (Z_{\alpha/2} + Z_\beta)^2 \sigma^2}{(\mu_1 - \mu_2)^2}$$
⚠️ Risk-Benefit Stratification
Non-significant risk (NSR) vs Significant Risk (SR) determination. Device biocompatibility (ISO 10993 cytotoxicity, sensitization, irritation) and electrical isolation certifications.
03. Grand Challenge Focus: Vulnerable Neonatal Human Subjects Protections
👶 Subpart D Protections for Neonatal Clinical Research
Under HHS 45 CFR 46 Subpart D, neonates and children are federally designated as vulnerable populations requiring elevated ethical safeguards:
📋 Parental Permission & Assent
In emergency HIE cooling protocols, obtaining informed parental consent during maternal post-delivery recovery requires sensitive, structured consent procedures. Both parents' permission is required for research involving greater than minimal risk without direct benefit.
🛡️ Prospect of Direct Clinical Benefit
To satisfy 45 CFR 46.405, investigational neuromonitoring must demonstrate a plausible prospect of direct benefit to the individual infant (e.g., early automated detection of occult status epilepticus) that justifies the risk of skin contact and sensor placement.